nach oben

Erschienen in:

25.06.2018 | Focussed Research Review

Dendritic cell trafficking in tumor-bearing mice

verfasst von: Sarah C. Krzastek, Ekaterine Goliadze, Shaoqing Zhou, Albert Petrossian, Fatma Youniss, Gobalakrishnan Sundaresan, Li Wang, Jamal Zweit, Georgi Guruli

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Prostate cancer is one of the leading causes of cancer deaths, with no curative treatments once it spreads. Alternative therapies, including immunotherapy, have shown limited efficacy. Dendritic cells (DC) have been widely used in the treatment of various malignancies. DC capture antigens and move to the lymphoid organs where they prime naive T cells. Interaction between DC and T cells are most active in lymph nodes and suppression of DC trafficking to lymph nodes impairs the immune response. In this work, we aimed to study trafficking of DC in vivo via various routes of delivery, to optimize the effectiveness of DC-based therapy. A DC labeling system was developed using 1,1′-dioctadecyltetramethyl indotricarbocyanine Iodine for in vivo fluorescent imaging. DC harvested from C57B/6 mice were matured, labeled, and injected intravenously, subcutaneously, or intratumorally, with or without antigen loading with whole tumor lysate, into C57B/6 mice inoculated with RM-1 murine prostate tumor cells. Signal intensity was measured in vivo and ex vivo. Signal intensity at the tumor site increased over time, suggesting trafficking of DC to the tumor with all modes of injection. Subcutaneous injection showed preferential trafficking to lymph nodes and tumor. Intravenous injection showed trafficking to lungs, intestines, and spleen. Subcutaneous injection of DC pulsed with whole tumor lysate resulted in the highest increase in signal intensity at the tumor site and lymph nodes, suggesting subcutaneous injection of primed DC leads to highest preferential trafficking of DC to the immunocompetent organs.

Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357. https://doi.org/10.1200/JCO.2005.00.240 CrossRefPubMedPubMedCentral

Yang JC, Rosenberg SA (2016) Adoptive T-cell therapy for cancer. Adv Immunol 130:279–294. https://doi.org/10.1016/bs.ai.2015.12.006 CrossRefPubMed

Zhang L, Zhu W, Li J, Yang X, Ren Y, Niu J, Pang Y (2016) Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol 4:129–133. https://doi.org/10.3892/mco.2015.660 CrossRefPubMed

Jiang P, Zhang Y, S JA, Wang H (2015) Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol 28:208–214. https://doi.org/10.1016/j.intimp.2015.05.042 CrossRefPubMed

Ernst B, Anderson KS (2015) Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 17:5. https://doi.org/10.1007/s11912-014-0426-9 CrossRefPubMed

Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257–e267. https://doi.org/10.1016/S1470-2045(13)70585-0 CrossRefPubMed

Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790–802. https://doi.org/10.1038/nri2173 CrossRefPubMed

Silvestri I, Cattarino S, Agliano AM, Collalti G, Sciarra A (2015) Beyond the immune suppression: the immunotherapy in prostate cancer. Biomed Res Int. 2015:794968. https://doi.org/10.1155/2015/794968 CrossRefPubMedPubMedCentral

Bianchi G, D’Amico G, Varone L, Sozzani S, Mantovani A, Allavena P (2000) In vitro studies on the trafficking of dendritic cells through endothelial cells and extra-cellular matrix. Dev Immunol 7:143–153CrossRef

10.

Demangel C, Bertolino P, Britton WJ (2002) Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 32:994–1002. https://doi.org/10.1002/1521-4141(200204)32:4<994::aid-immu994>3.0.co;2-6CrossRef

11.

Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. https://doi.org/10.1056/NEJMoa1001294 CrossRefPubMed

12.

Cho DY, Yang WK, Lee HC et al (2012) Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 77:736–744. https://doi.org/10.1016/j.wneu.2011.08.020 CrossRefPubMed

13.

Chiang CL, Kandalaft LE, Tanyi J et al (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19:4801–4815. https://doi.org/10.1158/1078-0432.CCR-13-1185 CrossRefPubMedPubMedCentral

14.

Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ (2013) Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev 39:891–907. https://doi.org/10.1016/j.ctrv.2013.05.007 CrossRefPubMed

15.

Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ (2014) Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 87:491–518PubMedPubMedCentral

16.

Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O'Reilly RJ (2007) In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res 67:11959–11969. https://doi.org/10.1158/0008-5472.CAN-07-1250 CrossRefPubMed

17.

Kircher MF, Gambhir SS, Grimm J (2011) Noninvasive cell-tracking methods. Nat Rev Clin Oncol 8:677–688. https://doi.org/10.1038/nrclinonc.2011.141 CrossRefPubMed

18.

Zhang Z, Li W, Procissi D et al (2015) Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model. Radiology 274:192–200. https://doi.org/10.1148/radiol.14132172 CrossRefPubMed

19.

Youniss FM, Sundaresan G, Graham LJ, Wang L, Berry CR, Dewkar GK, Jose P, Bear HD, Zweit J (2014) Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One 9:e109162. https://doi.org/10.1371/journal.pone.0109162 CrossRefPubMedPubMedCentral

20.

Christian NA, Benencia F, Milone MC, Li G, Frail PR, Therien MJ, Coukos G, Hammer DA (2009) In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol 11:167–177. https://doi.org/10.1007/s11307-008-0184-x CrossRefPubMedPubMedCentral

21.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRef

22.

Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223CrossRef

23.

So-Rosillo R, Small EJ (2006) Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 6:1163–1167. https://doi.org/10.1586/14737140.6.9.1163 CrossRefPubMed

24.

Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M (2011) Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6:e18801. https://doi.org/10.1371/journal.pone.0018801 CrossRefPubMedPubMedCentral

25.

Di Lorenzo G, Buonerba C, Kantoff PW (2011) Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:551–561. https://doi.org/10.1038/nrclinonc.2011.72 CrossRefPubMed

26.

Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith RA (2011) Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins. Biochem Soc Trans 39:1433–1436. https://doi.org/10.1042/bst0391433 CrossRefPubMed

27.

Probst HC, Muth S, Schild H (2014) Regulation of the tolerogenic function of steady-state DCs. Eur J Immunol 44:927–933. https://doi.org/10.1002/eji.201343862 CrossRefPubMed

28.

Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA (2009) Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci USA 106:20377–20381. https://doi.org/10.1073/pnas.0910295106 CrossRefPubMed

29.

Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277. https://doi.org/10.1038/nrc3258 CrossRefPubMedPubMedCentral

30.

Randolph GJ, Angeli V, Swartz MA (2005) Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617–628. https://doi.org/10.1038/nri1670 CrossRefPubMed

31.

Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P (2006) Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12:5801–5808. https://doi.org/10.1158/1078-0432.ccr-05-2421 CrossRefPubMedPubMedCentral

32.

Sozzani S, Luini W, Borsatti A et al (1997) Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159:1993–2000PubMed

33.

Caux C, Ait-Yahia S, Chemin K et al (2000) Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345–369CrossRef

34.

Smithson G, Rogers CE, Smith PL, Scheidegger EP, Petryniak B, Myers JT, Kim DS, Homeister JW, Lowe JB (2001) Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J Exp Med 194:601–614CrossRef

35.

Saiki T, Ezaki T, Ogawa M, Matsuno K (2001) Trafficking of host- and donor-derived dendritic cells in rat cardiac transplantation: allosensitization in the spleen and hepatic nodes. Transplantation 71:1806–1815CrossRef

36.

Penna G, Vulcano M, Sozzani S, Adorini L (2002) Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol 63:1164–1171CrossRef

37.

Vicari AP, Treilleux I, Lebecque S (2004) Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol 14:161–169. https://doi.org/10.1016/j.semcancer.2003.10.002 CrossRefPubMed

38.

Del Prete A, Shao WH, Mitola S, Santoro G, Sozzani S, Haribabu B (2007) Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109:626–631. https://doi.org/10.1182/blood-2006-02-003665 CrossRefPubMedPubMedCentral

39.

Chiang CL, Coukos G, Kandalaft LE (2015) Whole tumor antigen vaccines: where are we? Vaccines (Basel) 3:344–372. https://doi.org/10.3390/vaccines3020344 CrossRef

40.

Ramanathan P, Dhandapani H, Jayakumar H, Ganeshrajah S, Thangarajan R (2014) Dendritic cells primed with HPV positive cervical tumor lysate are superior to unprimed DCs in migratory capacity and induce a potent Th1 response. Hum Immunol 75:1216–1224. https://doi.org/10.1016/j.humimm.2014.09.020 CrossRefPubMed

41.

Rescigno M, Granucci F, Ricciardi-Castagnoli P (1999) Dendritic cells at the end of the millennium. Immunol Cell Biol 77:404–410. https://doi.org/10.1046/j.1440-1711.1999.00854.x CrossRefPubMed

Titel: Dendritic cell trafficking in tumor-bearing mice
verfasst von: Sarah C. Krzastek
Ekaterine Goliadze
Shaoqing Zhou
Albert Petrossian
Fatma Youniss
Gobalakrishnan Sundaresan
Li Wang
Jamal Zweit
Georgi Guruli
Publikationsdatum: 25.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2187-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Dendritic cell trafficking in tumor-bearing mice

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Cancer vaccine strategies: translation from mice to human clinical trials

The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer

Personalized cancer vaccines: adjuvants are important, too

Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma

Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie